STAT Plus: Pear Therapeutics licenses voice biomarkers for dementia and psychiatric disorders
Pear Therapeutics has struck a deal to license voice biomarkers to try to improve treatment…
Category: STAT Plus
STAT Plus: Pharmalittle: Few vets were treated with antidepressant Trump touted; Pelosi lashes out at price hikes
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts
Hello, Biotech 2020. True, we’re already six days into the new year, but the first…
STAT Plus: Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals
A federal judge dealt the pharmaceutical industry a setback by declining to block a new…
STAT Plus: Pharmalittle: Lab urges FDA to recall all forms of Zantac; end-of-year FDA approval rush has unintended consequence
And so, another working week will soon draw to a close. A little quicker than…
STAT Plus: The biotech scorecard for the first quarter: 14 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the first…
STAT Plus: An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment
Growing up in the 1970s, Jary Larsen heard his mother say their extended family had…
.jpg)
STAT Plus: It’s ‘business as usual’ as many drug makers boost prices for the new year
A new year often means higher prices for prescription medicines and 2020 is no exception….
STAT Plus: Pharmalittle: FDA failed to police opioid prescribing program; Novo launches plan to mitigate insulin cost
Good morning, everyone, and welcome to a new year. We hope the extended respite —…
STAT Plus: STAT’s guide to the most important, beneficial drugs approved in the past decade
The new year will end in a zero, making this a perfect opportunity to look…
STAT Plus: Crash and burn: The four biggest biopharma failures of 2019
In biotech, companies fail for a lot of reasons. The science might not quite work,…
STAT Plus: Sarepta sells international rights to Duchenne gene therapy to Roche
Sarepta Therapeutics said Monday that it will receive $1.15 billion in cash and an equity…
.jpg)
STAT Plus: Most Americans misunderstand approvals and FDA’s role in overseeing drug ads
The Food and Drug Administration may be a high-profile government agency, but a new survey…
STAT Plus: Prosecutors seek a 15-year jail sentence for former Insys CEO for his role in the opioid crisis
For his role in fomenting the opioid crisis, federal officials want to sentence Insys Therapeutics…
STAT Plus: Creating Pig3.0, the world’s most CRISPR’d animal, raises hopes of transplantable organs
A biotechnology company that is trying to create CRISPR-edited pigs so their organs could be…
STAT Plus: As families in Europe clamor for its pricey gene therapy, Novartis creates a lottery
Seeking to provide its pricey gene therapy to patients in countries where the drug is…
STAT Plus: One drug maker has a lot more to lose than others, under early drafts of drug importation plans
WASHINGTON — President Trump’s plan to let states and drug wholesalers import medicines from Canada…
STAT Plus: Pharmalittle: Trump proceeds with plan to allow importation; most Americans misunderstand FDA approvals
Hello, everyone, and how are you today? We are doing just splendidly, thank you, despite…
STAT Plus: Cutting-edge therapies promise one-time cures, but not without risk. Can biotech make them safer?
When Dr. Akshay Sharma sits down with his sickle cell disease patients to discuss potentially…
STAT Plus: Feds says a CVS long-term-care pharmacy improperly refilled prescriptions, jeopardizing patients
Omnicare, the nation’s largest long-term-care pharmacy, was accused by federal authorities of fraudulently billing government…
STAT Plus: Lawmakers slip a win for pharma into federal spending package
WASHINGTON — Lawmakers quietly tucked a boost for the pharmaceutical industry in the massive, end-of-year…
STAT Plus: In novel partnership with cancer group, biotech venture firm doles out grants for research
The whole point of a biotech venture capital firm is to make money for itself…
STAT Plus: Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation
Bankrupt microbiome-testing startup uBiome, once valued at $600 million by Silicon Valley investors, preliminarily sold…
STAT Plus: Axsome’s depression drug succeeds in late-stage trial
An experimental pill from Axsome Therapeutics had a rapid and significant effect on major depression…
STAT Plus: These 7 startups acquired by Apple are central to its health care strategy
Of all the tech companies aiming to shakeup health care, few have proclaimed as bold a…
STAT Plus: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year
In a surprise showing, the sale of medically important antibiotics given to food-producing livestock rose…
STAT Plus: Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: The good, the bad, and the really, really ugly behind Sarepta’s drug approval
What does it all mean now that the Food and Drug Administration has issued a…
STAT Plus: U.S. Patent Office removes lawyer from high-profile case involving a Gilead HIV medicine
The U.S. Patent and Trademark Office has removed a senior legal adviser from a high-profile…
STAT Plus: Biotech veteran Chris Garabedian on Sarepta’s legacy and Biogen’s future at the FDA
This September marked the third anniversary of a pivotal moment in biotech. Back in 2016,…
STAT Plus: Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups….
STAT Plus: After Ice Bucket campaign, researchers have optimism about insights into ALS puzzle
Five years after Pete Frates helped launch the Ice Bucket Challenge to raise awareness and…
STAT Plus: In tight Massachusetts job market, it’s relo for biotech and remote for tech hires
A state unemployment rate of 2.9% doesn’t quite capture how tight the job market is…
STAT Plus: With new trade deal, Trump deals a blow to drug makers
WASHINGTON — The Trump administration’s Tuesday agreement on a new trade deal with Canada and…
STAT Plus: GAO finds ongoing problems with FDA inspections of foreign drug facilities
Amid rising concern over the quality of the pharmaceutical supply chain, a government report finds…
STAT Plus: Watch: Dr. James Wilson, a scientific pioneer, on the future of gene therapy
Dr. James Wilson is a pioneer in gene therapy. That does not mean he is…
STAT Plus: Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’
ORLANDO, Fla. — In June, Dr. Samit Hirawat was appointed chief medical officer of Bristol-Myers…
STAT Plus: House Republicans fuel Capitol Hill chaos with competing drug pricing bill
WASHINGTON — Republicans on Monday are set to accelerate Capitol Hill’s drug pricing chaos with…
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
ORLANDO, Fla. — One year ago, a Chinese scientist stepped up to a podium at…
STAT Plus: New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind
ORLANDO, Fla. — On the eve of a major blood disease research meeting here, Bluebird…
STAT Plus: Lawmakers ask HHS for greater oversight of patient assistance programs
Amid ongoing concern about the use of patient assistance programs by the pharmaceutical industry, two…
STAT Plus: More hospital drug spending is going toward cancer immunotherapies
Amid intense scrutiny over prescription drug costs, a new analysis finds some hospitals are spending…
STAT Plus: Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict
Washington has never before been so focused on lowering prescription drug prices. But these biotech…
STAT Plus: Veritas, genetics company founded by George Church, suspends U.S. operations
Veritas Genetics, the Boston-based personal genome testing company co-founded by noted Harvard Medical School professor…
STAT Plus: Bribing doctors in India is allegedly a widespread practice
Seeking to juice profits, some Indian drug makers bribe doctors with credit cards, free trips,…
STAT Plus: More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill
WASHINGTON — Nearly 150 CEOs of emerging biotech companies are sending a unified, stark message…
STAT Plus: What side effects? Problems with medicines may be vastly underreported to the FDA
It’s no secret that the many side effects caused by medicines do not get reported…
STAT Plus: 4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug
The annual Alzheimer’s research meeting known as CTAD was supposed to be a snoozefest this…
STAT Plus: As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches
As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated…
STAT Plus: Senators urge Medicare to prevent bias in AI tools used in health care
Two Senate Democrats are challenging Medicare’s top official to investigate how health care tools based…